A Phase 1 Study of HCB303 in Participants With Advanced Malignancies

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
A Phase 1, Open-label, Multi-regional, Multicenter, Dose escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Antitumor Activity of HCB303 in Participants with Advanced Malignancies
Epistemonikos ID: 5767f3735d2712adefbdd915d7ea56d709becb93
First added on: Oct 06, 2026